Top

Published in:

01-09-2010 | Review

Targeting integrins in malignant glioma

Authors: Ghazaleh Tabatabai, Michael Weller, Burt Nabors, Martin Picard, David Reardon, Tom Mikkelsen, Curzio Ruegg, Roger Stupp

Published in: Targeted Oncology | Issue 3/2010

Abstract

The integrin family of cell adhesion receptors is emerging as a promising target of anticancer therapy. AlphaVbeta3 and alphaVbeta5 integrins are overexpressed on both glioma cells and tumor vasculature. Cilengitide, the most advanced specific integrin inhibitor in oncology, has shown antitumor activity against glioma in early clinical trials. Durable remissions have been observed in phase I and phase II trials for recurrent glioblastoma (GBM) with both lower and higher doses of cilengitide. Pilot trials in newly diagnosed glioblastoma in conjunction with standard chemoradiotherapy have been encouraging. Preclinical data suggest synergy with concomitant chemo- and radiation therapy. A pivotal phase III study (CENTRIC) in newly diagnosed GBM patients is currently recruiting. This paper summarizes the current understanding of the role of integrins and their inhibition in gliomagenesis. The background and design of ongoing trials are outlined.

Takada Y, Ye X, Simon S (2007) The integrins. Genome Biol 8(5):215. doi:10.1186/gb-2007-8-5-215 CrossRefPubMed

Desgrosellier JS, Cheresh DA (2010) Integrins in cancer: biological implications and therapeutic opportunities. Nat Rev Cancer 10(1):9–22. doi:10.1038/nrc2748 CrossRefPubMed

Ruegg C, Mariotti A (2003) Vascular integrins: pleiotropic adhesion and signaling molecules in vascular homeostasis and angiogenesis. Cell Mol Life Sci 60(6):1135–1157PubMed

Avraamides CJ, Garmy-Susini B, Varner JA (2008) Integrins in angiogenesis and lymphangiogenesis. Nat Rev Cancer 8(8):604–617. doi:10.1038/nrc2353 CrossRefPubMed

Alghisi GC, Ruegg C (2006) Vascular integrins in tumor angiogenesis: mediators and therapeutic targets. Endothelium 13(2):113–135CrossRefPubMed

Schnell O, Krebs B, Wagner E, Romagna A, Beer AJ, Grau SJ, Thon N, Goetz C, Kretzschmar HA, Tonn JC, Goldbrunner RH (2008) Expression of integrin alphavbeta3 in gliomas correlates with tumor grade and is not restricted to tumor vasculature. Brain Pathol 18(3):378–386. doi:10.1111/j.1750-3639.2008.00137.x CrossRefPubMed

Taga T, Suzuki A, Gonzalez-Gomez I, Gilles FH, Stins M, Shimada H, Barsky L, Weinberg KI, Laug WE (2002) Alpha v-integrin antagonist emd 121974 induces apoptosis in brain tumor cells growing on vitronectin and tenascin. Int J Cancer 98(5):690–697. doi:10.1002/ijc.10265 CrossRefPubMed

Bello L, Francolini M, Marthyn P, Zhang J, Carroll RS, Nikas DC, Strasser JF, Villani R, Cheresh DA, Black PM (2001) Alpha(v)beta3 and alpha(v)beta5 integrin expression in glioma periphery. Neurosurgery 49(2):380–389, discussion 390CrossRefPubMed

Beer AJ, Haubner R, Sarbia M, Goebel M, Luderschmidt S, Grosu AL, Schnell O, Niemeyer M, Kessler H, Wester HJ, Weber WA, Schwaiger M (2006) Positron emission tomography using [18f]galacto-rgd identifies the level of integrin alpha(v)beta3 expression in man. Clin Cancer Res 12(13):3942–3949. doi:10.1158/1078-0432.CCR-06-0266 CrossRefPubMed

10.

Wild-Bode C, Weller M, Wick W (2001) Molecular determinants of glioma cell migration and invasion. J Neurosurg 94(6):978–984. doi:10.3171/jns.2001.94.6.0978 CrossRefPubMed

11.

Maurer GD, Tritschler I, Adams B, Tabatabai G, Wick W, Stupp R, Weller M (2009) Cilengitide modulates attachment and viability of human glioma cells, but not sensitivity to irradiation or temozolomide in vitro. Neuro Oncol 11(6):747–756. doi:10.1215/15228517-2009-012 CrossRefPubMed

12.

Skuli N, Monferran S, Delmas C, Favre G, Bonnet J, Toulas C, Cohen-Jonathan Moyal E (2009) Alphavbeta3/alphavbeta5 integrins-fak-rhob: a novel pathway for hypoxia regulation in glioblastoma. Cancer Res 69(8):3308–3316. doi:10.1158/0008-5472.CAN-08-2158 CrossRefPubMed

13.

Lathia JD, Gallagher J, Heddleston JM, Wang J, Eyler CE, Macswords J, Wu Q, Vasanji A, McLendon RE, Hjelmeland AB, Rich JN (2010) Integrin alpha 6 regulates glioblastoma stem cells. Cell Stem Cell 6(5):421–432. doi:10.1016/j.stem.2010.02.018 CrossRefPubMed

14.

Ruegg C, Alghisi GC (2010) Vascular integrins: therapeutic and imaging targets of tumor angiogenesis. Recent Results Cancer Res 180:83–101. doi:10.1007/978-3-540-78281-0_6 CrossRefPubMed

15.

Garcia-Barros M, Paris F, Cordon-Cardo C, Lyden D, Rafii S, Haimovitz-Friedman A, Fuks Z, Kolesnick R (2003) Tumor response to radiotherapy regulated by endothelial cell apoptosis. Science 300(5622):1155–1159. doi:10.1126/science.1082504300/5622/1155 CrossRefPubMed

16.

Nieder C, Wiedenmann N, Andratschke NH, Astner ST, Molls M (2007) Radiation therapy plus angiogenesis inhibition with bevacizumab: rationale and initial experience. Rev Recent Clin Trials 2(3):163–168CrossRefPubMed

17.

Fenton BM, Paoni SF (2007) The addition of ag-013736 to fractionated radiation improves tumor response without functionally normalizing the tumor vasculature. Cancer Res 67(20):9921–9928. doi:10.1158/0008-5472.CAN-07-1066 CrossRefPubMed

18.

Shinohara ET, Cao C, Niermann K, Mu Y, Zeng F, Hallahan DE, Lu B (2005) Enhanced radiation damage of tumor vasculature by mtor inhibitors. Oncogene 24(35):5414–5422. doi:10.1038/sj.onc.1208715 CrossRefPubMed

19.

Albert JM, Cao C, Geng L, Leavitt L, Hallahan DE, Lu B (2006) Integrin alpha v beta 3 antagonist cilengitide enhances efficacy of radiotherapy in endothelial cell and non-small-cell lung cancer models. Int J Radiat Oncol Biol Phys 65(5):1536–1543. doi:10.1016/j.ijrobp.2006.04.036 PubMed

20.

Wachsberger P, Burd R, Dicker AP (2004) Improving tumor response to radiotherapy by targeting angiogenesis signaling pathways. Hematol Oncol Clin North Am 18(5):1039–1057. doi:10.1016/j.hoc.2004.06.007, viiiCrossRefPubMed

21.

Wild-Bode C, Weller M, Rimner A, Dichgans J, Wick W (2001) Sublethal irradiation promotes migration and invasiveness of glioma cells: implications for radiotherapy of human glioblastoma. Cancer Res 61(6):2744–2750PubMed

22.

Mikkelsen T, Brodie C, Finniss S, Berens ME, Rennert JL, Nelson K, Lemke N, Brown SL, Hahn D, Neuteboom B, Goodman SL (2009) Radiation sensitization of glioblastoma by cilengitide has unanticipated schedule-dependency. Int J Cancer 124(11):2719–2727. doi:10.1002/ijc.24240 CrossRefPubMed

23.

Reynolds AR, Hart IR, Watson AR, Welti JC, Silva RG, Robinson SD, Da Violante G, Gourlaouen M, Salih M, Jones MC, Jones DT, Saunders G, Kostourou V, Perron-Sierra F, Norman JC, Tucker GC, Hodivala-Dilke KM (2009) Stimulation of tumor growth and angiogenesis by low concentrations of RGD-mimetic integrin inhibitors. Nat Med 15(4):392–400. doi:10.1038/nm.1941 CrossRefPubMed

24.

Weller M, Reardon D, Nabors B, Stupp R (2009) Will integrin inhibitors have proangiogenic effects in the clinic? Nat Med 15(7):726. doi:10.1038/nm0709-726, author reply 727CrossRefPubMed

25.

Nabors B, Mikkelsen T, Rosenfeld S, Hochberg F, Shastry Akella N, Fisher J, Cloud G, Zhang Y, Carson K, Wittemer S, Colvevas D, Grossman S, for the NABTT CNS Consortium (2007) A phase I and correlative biology study of cilengitide in patients with recurrent malignant glioma. J Clin Oncol 25(13):1651–1657CrossRefPubMed

26.

Abdollahi A, Griggs DW, Zieher H, Roth A, Lipson KE, Saffrich R, Grone HJ, Hallahan DE, Reisfeld RA, Debus J, Niethammer AG, Huber PE (2005) Inhibition of alpha(V)beta3 integrin survival signaling enhances antiangiogenic and antitumor effects of radiotherapy. Clin Cancer Res 11(17):6270–6279CrossRefPubMed

27.

Abdollahi A, Folkman J (2010) Evading tumor evasion: current concepts and perspectives of anti-angiogenic cancer therapy. Drug Resist Updat 13(1–2):16–28. doi:10.1016/j.drup.2009.12.001 CrossRefPubMed

28.

Imaizumi N, Monnier Y, Hegi M, Mirimanoff RO, Ruegg C (2010) Radiotherapy suppresses angiogenesis in mice through tgf-betari/alk5-dependent inhibition of endothelial cell sprouting. PLoS ONE 5(6):e11084. doi:10.1371/journal.pone.0011084 CrossRefPubMed

29.

Monnier Y, Farmer P, Bieler G, Imaizumi N, Sengstag T, Alghisi GC, Stehle JC, Ciarloni L, Andrejevic-Blant S, Moeckli R, Mirimanoff RO, Goodman SL, Delorenzi M, Ruegg C (2008) Cyr61 and alphaVbeta5 integrin cooperate to promote invasion and metastasis of tumors growing in preirradiated stroma. Cancer Res 68(18):7323–7331. doi:10.1158/0008-5472.CAN-08-0841 CrossRefPubMed

30.

Leask A, Abraham DJ (2006) All in the ccn family: essential matricellular signaling modulators emerge from the bunker. J Cell Sci 119(Pt 23):4803–4810. doi:10.1242/jcs.03270 CrossRefPubMed

31.

Mitjans F, Sander D, Adan J, Sutter A, Martinez JM, Jaggle CS, Moyano JM, Kreysch HG, Piulats J, Goodman SL (1995) An anti-alpha V-integrin antibody that blocks integrin function inhibits the development of a human melanoma in nude mice. J Cell Sci 108(Pt 8):2825–2838PubMed

32.

Chan DA, Giaccia AJ (2007) Hypoxia, gene expression, and metastasis. Cancer Metastasis Rev 26(2):333–339. doi:10.1007/s10555-007-9063-1 CrossRefPubMed

33.

Paez-Ribes M, Allen E, Hudock J, Takeda T, Okuyama H, Vinals F, Inoue M, Bergers G, Hanahan D, Casanovas O (2009) Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 15(3):220–231. doi:10.1016/j.ccr.2009.01.027 CrossRefPubMed

34.

Xiong JP, Stehle T, Zhang R, Joachimiak A, Frech M, Goodman SL, Arnaout MA (2002) Crystal structure of the extracellular segment of integrin alphaVbeta3 in complex with an arg-gly-asp ligand. Science 296(5565):151–155. doi:10.1126/science1069040 CrossRefPubMed

35.

Goodman SL, Holzemann G, Sulyok GA, Kessler H (2002) Nanomolar small molecule inhibitors for alphaV(beta)6, alphaV(beta)5, and alphaV(beta)3 integrins. J Med Chem 45(5):1045–1051. doi:jm0102598 CrossRefPubMed

36.

Nisato RE, Tille JC, Jonczyk A, Goodman SL, Pepper MS (2003) AlphaV beta 3 and alphav beta 5 integrin antagonists inhibit angiogenesis in vitro. Angiogenesis 6(2):105–119. doi:10.1023/B:AGEN.0000011801.98187.f25255607 CrossRefPubMed

37.

MacDonald TJ, Taga T, Shimada H, Tabrizi P, Zlokovic BV, Cheresh DA, Laug WE (2001) Preferential susceptibility of brain tumors to the antiangiogenic effects of an alpha(V) integrin antagonist. Neurosurgery 48(1):151–157CrossRefPubMed

38.

Eskens FA, Dumez H, Hoekstra R, Perschl A, Brindley C, Bottcher S, Wynendaele W, Drevs J, Verweij J, van Oosterom AT (2003) Phase I and pharmacokinetic study of continuous twice weekly intravenous administration of cilengitide (EMD 121974), a novel inhibitor of the integrins alphavbeta3 and alphavbeta5 in patients with advanced solid tumours. Eur J Cancer 39(7):917–926. doi:S0959804903000571 CrossRefPubMed

39.

MacDonald TJ, Stewart CF, Kocak M, Goldman S, Ellenbogen RG, Phillips P, Lafond D, Poussaint TY, Kieran MW, Boyett JM, Kun LE (2008) Phase I clinical trial of cilengitide in children with refractory brain tumors: pediatric brain tumor consortium study pbtc-012. J Clin Oncol 26(6):919–924. doi:10.1200/JCO.2007.14.1812 CrossRefPubMed

40.

Stupp R, Ruegg C (2007) Integrin inhibitors reaching the clinic. J Clin Oncol 25(13):1637–1638CrossRefPubMed

41.

Reardon DA, Fink KL, Mikkelsen T, Cloughesy TF, O’Neill A, Plotkin S, Glantz M, Ravin P, Raizer JJ, Rich KM, Schiff D, Shapiro WR, Burdette-Radoux S, Dropcho EJ, Wittemer SM, Nippgen J, Picard M, Nabors LB (2008) Randomized phase II study of cilengitide, an integrin-targeting arginine-glycine-aspartic acid peptide, in recurrent glioblastoma multiforme. J Clin Oncol 26(34):5610–5617. doi:10.1200/JCO.2008.16.7510 CrossRefPubMed

42.

Fink K, Mikkelsen T, Nabors LB, Ravin P, Plotkin SR, Schiff D, Hicking C, Picard M, Reardon DA (2010) Long-term effects of cilengitide, a novel integrin inhibitor, in recurrent glioblastoma: a randomized phase IIa study. Proc Am Soc Clin Oncol, J Clin Oncol 28(suppl):15s, abstract 2010

43.

Nabors L, Mikkelsen T, Batchelor T, Lesser G, Rosenfeld M, Ye X, Piantadosi S, Olson J, Brem S, Grossman S (2009) Nabtt 0306: A randomized phase II trial of EMD 121974 in conjunction with concomitant and adjuvant temozolomide with radiation therapy in patients with newly diagnosed glioblastoma multiforme (GBM). Proc Am Soc Clin Oncol, J Clin Oncol 27:15s, suppl; abstract 2001

44.

Gilbert M, Lamborn K, Lassman A, Cloughesy T, Chang S, Lieberman F, Wen P, Poetzsch S, Picard M, Prados M, Kuhn J, for the North American Brain Tumor Consortium (2007) Tumor tissue delivery of cilengitide fater intravenous administration to patients with recurrent glioblastoma. Preliminary data from NABTC protocol 03–02. Neuro Oncol 4:525

45.

Stupp R, Hegi ME, Neyns B, Goldbrunner R, Schlegel U, Clement PM, Grabenbauer GG, Ochsenbein AF, Simon M, Dietrich PY, Pietsch T, Hicking C, Tonn JC, Diserens AC, Pica A, Hermisson M, Krueger S, Picard M, Weller M (2010) Phase I/IIa study of cilengitide and temozolomide with concomitant radiotherapy followed by cilengitide and temozolomide maintenance therapy in patients with newly diagnosed glioblastoma. J Clin Oncol 28(16):2712–2718. doi:10.1200/JCO.2009.26.6650 CrossRefPubMed

46.

Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352(10):987–996CrossRefPubMed

47.

Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, Janzer RC, Ludwin SK, Allgeier A, Fisher B, Belanger K, Hau P, Brandes AA, Gijtenbeek J, Marosi C, Vecht CJ, Mokhtari K, Wesseling P, Villa S, Eisenhauer E, Gorlia T, Weller M, Lacombe D, Cairncross JG, Mirimanoff RO (2009) Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 10(5):459–466. doi:10.1016/S1470-2045(09)70025-7 CrossRefPubMed

48.

Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, Weller M, Kros JM, Hainfellner JA, Mason W, Mariani L, Bromberg JE, Hau P, Mirimanoff RO, Cairncross JG, Janzer RC, Stupp R (2005) MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352(10):997–1003CrossRefPubMed

49.

Stupp R, Van Den Bent MJ, Erridge SC, Reardon DA, Hong Y, Wheeler H, Hegi M, Perry JR, Picard M, Weller M (2010) Cilengitide in newly diagnosed glioblastoma with MGMT promoter methylation: protocol of a multicenter, randomized, open-label, controlled phase III trial (CENTRIC). Proc Am Soc Clin Oncol, J Clin Oncol 28:15s, suppl; abstr TPS152

Title: Targeting integrins in malignant glioma
Authors: Ghazaleh Tabatabai
Michael Weller
Burt Nabors
Martin Picard
David Reardon
Tom Mikkelsen
Curzio Ruegg
Roger Stupp
Publication date: 01-09-2010
Publisher: Springer-Verlag
Published in: Targeted Oncology / Issue 3/2010
Print ISSN: 1776-2596
Electronic ISSN: 1776-260X
DOI: https://doi.org/10.1007/s11523-010-0156-3

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2010

Immune therapeutic targeting of glioma cancer stem cells

Novel targeted agents for platelet-derived growth factor receptor and c-KIT in malignant gliomas

Targeted therapies on the horizon for malignant glioma

Vascular endothelial growth factor inhibitors in malignant gliomas

Glioma stem cells as a target for treatment

Molecular markers in gliomas: impact for the clinician

Keynote webinar | Spotlight on antibody–drug conjugates in cancer